Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Arrowhead Pharmaceuticals (ARWR) Depreciation & Amortization (IS) (2016 - 2017)

Arrowhead Pharmaceuticals' Depreciation & Amortization (IS) history spans 7 years, with the latest figure at $1.1 million for Q4 2017.

  • For Q4 2017, Depreciation & Amortization (IS) fell 3.75% year-over-year to $1.1 million; the TTM value through Dec 2017 reached $4.6 million, up 27.24%, while the annual FY2017 figure was $4.7 million, 43.88% up from the prior year.
  • Depreciation & Amortization (IS) reached $1.1 million in Q4 2017 per ARWR's latest filing, down from $1.2 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (IS) ranged from a high of $9.2 million in Q3 2013 to a low of $276054.0 in Q2 2014.
  • Average Depreciation & Amortization (IS) over 5 years is $1.2 million, with a median of $803912.0 recorded in 2016.
  • Peak YoY movement for Depreciation & Amortization (IS): plummeted 39.21% in 2014, then skyrocketed 173.88% in 2015.
  • A 5-year view of Depreciation & Amortization (IS) shows it stood at $403405.0 in 2013, then dropped by 28.1% to $290039.0 in 2014, then surged by 173.88% to $794349.0 in 2015, then soared by 49.26% to $1.2 million in 2016, then decreased by 3.75% to $1.1 million in 2017.
  • Per Business Quant, the three most recent readings for ARWR's Depreciation & Amortization (IS) are $1.1 million (Q4 2017), $1.2 million (Q3 2017), and $1.2 million (Q2 2017).